Stereotactic radiosurgery is now a treatment option for meningiomas, especially for high-risk patients such as those with skull base lesions. The clinical outcomes were retrospectively analyzed of stereotactic radiosurgery using the Leksell Gamma Knife  performed for 98 patients with 106 skull base meningiomas at the University of Tokyo Hospital between June 1990 and April 2006 and followed up for more than a year. After a median follow-up period of 53.2 months (range 12.2-204.4 months), local tumor control rates were 86.9% and 78.9% at 5 years and 10 years, respectively. Tumors with volume of 4 cm 3 or smaller (97.5% vs. 76.1% at 5 years, p ＝ 0.001) and tumors completely included within the isodose line of 14 Gy or more (97.5% vs. 67.2% at 5 years, p ＝ 0.0006) had higher local control rates. Postoperative residual tumors treated by stereotactic radiosurgery were controlled in all 25 cases. Cranial nerve deficits were improved, stable, and deteriorated in 12, 64, and 3 patients, respectively, after stereotactic radiosurgery. Stereotactic radiosurgery was effective treatment method for local control of skull base meningiomas, especially for small or postoperative residual tumors. Correct combination of microsurgery and radiosurgery leads to excellent local control.
Introduction
Meningioma is the most common type of intracranial tumor arising from the meninges, with an incidence of 4.5 per 100,000 person-years, and accounts for 30.1% of all primary brain and central nervous system tumors. 3) The standard treatment for meningioma is surgical resection through craniotomy, targeted at gross total removal. 2, 4, 6, 9, 16, 23, 24, 31, 35) The treatment goal is longterm tumor control with minimal neurological morbidity. However, the tumor often extends to important neurovascular structures in the skull base, so total tumor resection (Simpson grades 1-2) is achieved in only 20-87.5% of patients. 2, 4, 23, 24, 31, 35) Unacceptably high incidences of symptomatic recurrence are observed after subtotal resection of meningiomas. 20, 33) In addition, postoperative complications occur in 16.1-61.5% of patients, although overall complication rates are not always reported. 2, 23, 31, 35) Stereotactic radiosurgery has now become a less invasive and effective treatment option for intracranial meningioma, especially in patients with high-risk tumors such as skull base lesions. 1, [11] [12] [13] [14] [15] [16] 18, 19, 21, 22, 26, 27, 30, 32, 34, 37) Stereotactic radiosurgery provides excellent outcomes with local tumor control rates of 85-100%, but these rates tend to fall with longer follow-up periods. [11] [12] [13] [14] [15] 18, 19, 21, 26, 27, 30, 32, 34) However, recent local tumor control rates have been nearly 100% for patients who had undergone Simpson grade 1 surgery. 16, 28) Therefore, correct combination of microsurgery and radiosurgery would seem to have attained better clinical results with cavernous sinus meningiomas in our earlier series and in other institutions. 5, 7, 10, 17, 19, 25) The Leksell Gamma Knife  (Elekta Instruments AB, Stockholm, Sweden) was installed in 1990 at the University of Tokyo Hospital. Since then, we have treated patients with intracranial tumors by stereotactic radiosurgery as a single modality treatment or in combination with surgery.
This study retrospectively reviewed the outcomes of stereotactic radiosurgery for skull base meningioma at the University of Tokyo Hospital and analyzed the factors affecting the results. GKS: gamma knife surgery, NOS: not others specified. 
Materials and Methods
Ninety-eight patients with 106 skull base meningiomas were treated by stereotactic radiosurgery, twice in 6 patients and three times in one patient, at the University of Tokyo Hospital and followed up for more than a year between June 1990 and April 2006.
The clinical courses and treatment outcomes were retrospectively analyzed (Table 1) . Written informed consent was obtained from the patients before treatment. The patients were immobilized with a Leksell stereotactic coordinating frame and underwent high-resolution stereotactic magnetic resonance (MR) imaging or computed tomography (CT). The treatment plan was based on the stereotactic images processed with commercially available software (KULA or GammaPlan; Elekta Instruments AB). The tumor was generally covered with the 40-50% isodose line, and the designated treatment dose (ideally 14 to 18 Gy) was delivered to the tumor margin.
The patients were followed up to monitor local tumor control, survival, and neurological status at our hospitals or by the referring physicians. Neurological evaluations and MR imaging were performed 3, 6, and 12 months after stereotactic radiosurgery, then every 6 months for the next 2 years, and annually thereafter. Follow-up and survival periods were calculated from the day of stereotactic radiosurgery. Actuarial local control and survival rates were calculated by the Kaplan-Meier method from the day of stereotactic radiosurgery. Local control was defined as free from local tumor regrowth after stereotactic radiosurgery as evaluated by MR imaging. The differences between groups was assessed with the log-rank test. Differences were considered statistically significant if p º 0.05.
Results
Local tumor progression was observed in 15 patients after a median follow-up period of 53.2 months (range 12.2-204.4 months) after stereotactic radiosurgery. Actuarial local tumor control rates were 86.9% and 78.9% at 5 years and 10 years, respectively (Fig. 1) . The tumors with volume of 4 cm 3 or smaller had a higher local control rate than those with volume of larger than 4 cm 3 (97.5% vs. 76.1% at 5 years, p ＝ 0.001) (Fig. 2A) . Local control rates were also better in tumors with the entire volume included within the isodose line of 14 Gy or more than tumors with incomplete coverage by the 14 Gy isodose line (97.5% vs. 67.2% at 5 years, p ＝ 0.0006) (Fig. 2B) . Treatment dose at the tumor margin and stereotactic images used for treatment planning did not influence local tumor control (90.9% for doses higher than 16 Gy vs. 85.3% for doses of 16 Gy or lower at 5 years, p ＝ 0.41; 88.0% by MR imaging vs. 85.3% by CT at 5 years, p ＝ 0.99) (Fig. 3) . Postoperative residual tumors treated with stereotactic radiosurgery as an adjuvant modality were controlled in all 25 cases, but the local control rate of the recurrent and untreated tumors treated with only stereotactic radiosurgery was 89.7% and 75.5% at 5 years, respectively, which was apparently inferior to the local control rate of 100% achieved by the twostaged strategy (Fig. 4) . Overall survival rates were 92.5% and 92.5% at 5 years and 10 years, respectively (Fig. 1) . Eighty patients had cranial nerve deficits before stereotactic radiosurgery. Improvement was observed in 12 patients and worsening of the symptoms present at the treatment in 2 patients after the treatment. Cranial nerve deficits remained stable in the other 66 patients. Newly developed permanent radiation-induced cranial nerve deficits were noted in one patient after stereotactic radiosurgery. Cranial nerve functions are summarized in Table 2 .
Discussion
The present study showed that tumor volume of 4 cm 3 or smaller and complete tumor coverage were associated with better local control (Fig. 2) . In addition, local control was apparently superior in the patients treated by stereotactic radiosurgery for postoperative residual tumor compared to treatment for recurrent tumor or single modality stereotactic radiosurgery treatment (Fig. 4) . This difference presumably reflected the tumor debulking by surgical intervention before stereotactic radiosurgery, resulting in the beneficial condition of smaller tumor volume at the time of stereotactic radiosur- 
*Improvement of at least one cranial nerve symptom with no worsening of any cranial nerve symptom. **Deterioration of symptom which had been observed before GKS. ***New development of symptom which had not existed before GKS.
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Local control rates showed no significant difference between patients treated by MR imaging-based planning and by CT-based planning (Fig. 3B) . Tumor volume delineated by MR imaging is known to differ considerably from that by CT. 29) In addition, MR imaging has a problem of image distortion, which can influence the setup error. 36) However, the stereotactic images used in the treatment planning did not affect the local tumor control in our experience, or in previous similar findings. 8) The crude post-radiosurgical permanent complication rate of 3% (3/98 patients, Table 2 ) was not negligible, and longer follow-up periods might reveal higher complication rates, but our experience with skull base meningiomas was similar to that of other institutions. The median margin dose of 16 Gy was higher than that used at other institutions. We selected higher doses for skull base meningioma treatment because of the probable miserable consequences for local recurrence after stereotactic radiosurgery. Lower treatment dose is associated with reduced incidence of radiation-induced morbidities after stereotactic radiosurgery, and some investigators reported no influence on local tumor control. 11, 22) Local tumor control rates for skull base meningiomas after stereotactic radiosurgery were better in the patients with tumor volumes of 4 cm 3 or smaller, and the patients treated with adjuvant stereotactic radiosurgery for postoperative residual tumors. If the volume of the skull base meningioma is 4 cm 3 or smaller, the tumor can be treated by single modality stereotactic radiosurgery with good local control rate. If the tumor volume is larger than 4 cm 3 , combined microsurgery and postoperative stereotactic radiosurgery is required if any residual tumor is detected postoperatively. Correct combination of the two modalities leads to excellent local tumor control.
Stereotactic Radiosurgery for Skull Base Meningioma suggested by the authors that skull base meningiomas even up to the size of 4 cm 2 can or should be treated by radiation treatment, it has to be clearly understood by neurosurgeons that surgery is superior and better for all tumors, from scalp to sole, including meningiomas. It is only in cases where surgery is not possible or is dangerous beyond reasonable limits, radiation may be used as a primary`palliative' form of treatment. 1) Despite the success obtained by the authors, in recurrent or residual tumors, the role of radiation treatment for skull base meningiomas can at best be considered to be still under evaluation. It needs to be appreciated that the so-called base of the skull is fillin-the-gap osseation between a jungle of neurovascular structures that traverse to-and-from the brain. All neurovascular structures are too precious to be trifled with by any radiation. Radiation offers short-term gain but spawns long-term, obstinate side-effects. One might summarize that anticytotic therapy (chemotherapy, radiotherapy) shall only be reserved for sites inaccessible to the knife.
